Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: A pilot randomized double-blind trial

Diabetes, Obesity and Metabolism

Volumn 13, Issue 2, 2011, Pages 137-143

  Garg, S K ^a,b   Ritchie, P J ^a   Moser, E G ^a   Snell Bergeon, J K ^a   Freson, B J ^a   Hazenfield, R M ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

A1c; Bile acid sequestrants; Cardiovascular disease; Cholesterol; Colesevelam; GLP 1; Glycaemic control; Hypercholesterolaemia; Low density lipoprotein; Type 1 diabetes

Indexed keywords

COLESEVELAM; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIABETIC PATIENT; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PATIENT COMPLIANCE; PILOT STUDY; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 78650670934     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01320.x     Document Type: Article

References (21)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
3. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 2003; 290: 2159-2167.
4. Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
5. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33: S11-61.
6. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
7. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-219.
8. Dalla Man C, Bock G, Giesler PD et al. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care 2009; 32: 14-18.
9. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99: 257-273.
10. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord 2009; 7: 255-258.
11. Heller DP, Burke SK, Davidson DM, Donovan JM. Absorption of colesevelam hydrochloride in healthy volunteers. Ann Pharmacother 2002; 36: 398-403.
12. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24.
13. Nervi FO, Gonzalez A, Valdivieso VD. Studies on cholesterol metabolism in the diabetic rat. Metabolism 1974; 23: 495-503.
14. Wey HE, Yunker RL, Harris P, Subbiah MT. Effect of streptozotocin-induced diabetes in neonatal rat on bile acid pool changes in adult life: selective sensitivity in females. Biochem Med 1984; 31: 167-173.
15. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2009; 168: 1975-1983.
16. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008; 168: 1531-1540.
17. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL-C cholesterol with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31: 1479-1484.
18. Fonseca VA, Handelsam Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metabol 2010; 12: 384-392.
19. Braunlin W, Zhorov E, Smisek D. In vitro comparasin of bile acid binding to colesevelam HCL and other bile acid sequestrants. Polymer Preprint 2000; 41: 708-709.
20. The Lipid Research Clinics Coronary Primary Prevention Trial results. I: Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
21. Schwartz SL, Lai YL, Xu J et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord 2010; 8: 179-187.